BPMC — Blueprint Medicines Cashflow Statement
0.000.00%
Last trade - 00:00- $8.37bn
- $8.18bn
- $508.82m
- 50
- 12
- 84
- 47
Annual cashflow statement for Blueprint Medicines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 314 | -644 | -558 | -507 | -67.1 |
| Depreciation | |||||
| Non-Cash Items | 82.2 | 363 | 97.3 | 99.6 | -77.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -15.6 | -23.7 | -53.8 | -41.1 | -64.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 387 | -299 | -502 | -437 | -193 |
| Capital Expenditures | -3.16 | -3.09 | -8.92 | -16.1 | -4.63 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -431 | -223 | -141 | 290 | -42.9 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -434 | -226 | -150 | 274 | -47.5 |
| Financing Cash Flow Items | 0 | 0 | 416 | -0.044 | 48.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 618 | 50.7 | 562 | 119 | 273 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 570 | -475 | -90.2 | -43.4 | 32.1 |